NASDAQ:ASLN - ASLAN PHARMACEU/ADR Stock Price, Forecast & News

ASLAN PHARMACEU/ADR trades on the NASDAQ under the ticker symbol "ASLN."

ASLAN PHARMACEU/ADR is scheduled to release their next quarterly earnings announcement on Friday, March 27th 2020. View Earnings Estimates for ASLAN PHARMACEU/ADR.

3 brokers have issued 1 year price targets for ASLAN PHARMACEU/ADR's stock. Their forecasts range from $5.00 to $8.00. On average, they anticipate ASLAN PHARMACEU/ADR's stock price to reach $6.50 in the next year. This suggests a possible upside of 238.5% from the stock's current price. View Analyst Price Targets for ASLAN PHARMACEU/ADR.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN PHARMACEU/ADR in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ASLAN PHARMACEU/ADR.

News coverage about ASLN stock has trended somewhat negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. ASLAN PHARMACEU/ADR earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for ASLAN PHARMACEU/ADR.

Some companies that are related to ASLAN PHARMACEU/ADR include Hookipa Pharma (HOOK), VBI Vaccines (VBIV), Seres Therapeutics (MCRB), BIOFRONTERA AG/ADR (BFRA), MEI Pharma (MEIP), Ocular Therapeutix (OCUL), Advanz Pharma (CXRXF), IVERIC bio (ISEE), Kalvista Pharmaceuticals (KALV), Protagonist Therapeutics (PTGX), Geron (GERN), XOMA (XOMA), Kala Pharmaceuticals (KALA), Sol Gel Technologies (SLGL) and Aeglea Bio Therapeutics (AGLE).

Based on aggregate information from My MarketBeat watchlists, some companies that other ASLAN PHARMACEU/ADR investors own include Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Actinium Pharmaceuticals (ATNM), Opko Health (OPK), Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA), Cidara Therapeutics (CDTX), Ocugen (OCGN) and Oncolytics Biotech (ONCY).

(ASLN) raised $60 million in an initial public offering on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray served as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

ASLAN PHARMACEU/ADR's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Marshall Wace LLP (0.30%), Bank of America Corp DE (0.25%), Virtu Financial LLC (0.17%) and Renaissance Technologies LLC (0.05%).

ASLN stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Bank of America Corp DE, Virtu Financial LLC and Renaissance Technologies LLC.

Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ASLN stock can currently be purchased for approximately $1.92.

ASLAN PHARMACEU/ADR has a market capitalization of $61.54 million. The company earns $-42,190,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. View Additional Information About ASLAN PHARMACEU/ADR.

The official website for ASLAN PHARMACEU/ADR is http://aslanpharma.com/.

ASLAN PHARMACEU/ADR's mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at 65-6222-4235 or via email at [email protected]